University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
James L. Rubenstein, MD, PhD

James L. Rubenstein, MD, PhD

Professor in Residence, Department of Medicine, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Education

Stanford University, B.S., June 1985, Biological Sciences
The Rockefeller University, Ph.D., June 1991, Molecular and Cellular Neuroscience (Medical Scientist Training Program)
Cornell University Medical College, M.D., May 1992, Medicine
Stanford University Medical Center, Stanford, CA, Internship/Residency, 1992-1995, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 1992-1998, Hematology/Oncology and Neuro-Oncology


Professional Experience

  • 1998-2006
    Assistant Adjunct Professor of Medicine, Attending Physician in Hematology/Oncology, University of California, San Francisco
  • 2006-2009
    Assistant Professor of Medicine in Residence, University of California, San Francisco
  • 2009-2013
    Associate Professor of Medicine in Residence, University of California, San Francisco
  • 2013-present
    Professor in Residence, Department of Medicine, University of California, San Francisco

Honors & Awards

  • 1985
    Phi Beta Kappa
  • 1985
    Departmental Honors in Biological Sciences
  • 1985
    Honors in Humanities
  • 1995
    Housestaff Research Award
  • 1998
    Young Investigator Award -American Society of Clinical Oncology
  • 1999
    American Brain Tumor Association Fellowship
  • 2000
    UCSF/Mt Zion Clinical Investigator Research Program
  • 2000
    California Cancer Research Program Clinical Scientist Development Award
  • 2001
    UCSF/Mt Zion Clinical Investigator Research Program
  • 2001
    Career Development Award-American Society of Clinical Oncology
  • 2001
    Accelerate Brain Cancer Cure Foundation Award
  • 2002
    UCSF Research Evaluation and Allocation Committee Award
  • 2003
    UC Discovery Grant
  • 2003
    Tobacco-Related Disease Research Program IDEA Award
  • 2004
    National Cancer Institute Research Career Award
  • 2004
    American Cancer Society Award
  • 2005
    UCSF Brain Tumor SPORE Development Award
  • 2006
    G&P Foundation Award
  • 2008
    UCSF Clinical and Translational Sciences Grant
  • 2009
    Scholar in Clinical Research Award, Leukemia & Lymphoma Society
  • 2011
    Sandler Award Program in Breakthrough Biomedical Research
  • 2013
    Translational Research Program Award, Leukemia & Lymphoma Society
    Invited Lectures

Selected Publications

  1. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Ka/d and HDAC. J Invest Dermatol. 2020 Jun 27.
    View on PubMed
  2. Tsang M, Cleveland J, Rubenstein JL. On Point in Primary CNS Lymphoma. Hematol Oncol. 2020 Jun 08.
    View on PubMed
  3. Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John Paul Leonard, James L. Rubenstein. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):8042-8042.
    View on PubMed
  4. Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. Retin Cases Brief Rep. 2020; 14(2):116-119.
    View on PubMed
  5. David A. Solomon, Huimin Geng, Raymond A. Sobel, Lakshmi Subbaraj, Mazie Tsang, James L. Rubenstein. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood. 2019 Nov 13; 134(Supplement_1):1494-1494.
    View on PubMed
  6. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol. 2019 08 01; 30(8):1397-1398.
    View on PubMed
  7. Damato B, Bever GJ, Kim DJ, Afshar AR, Rubenstein JL. An audit of retinal lymphoma treatment at the University of California San Francisco. Eye (Lond). 2020 Mar; 34(3):515-522.
    View on PubMed
  8. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:454-466.
    View on PubMed
  9. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019 02 19; 21(3):296-305.
    View on PubMed
  10. Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019 07; 186(1):180-183.
    View on PubMed
  11. Huimin Geng, Brice Tiret, Hua-Xin Gao, Cigall Kadoch, Ming Lu, Lingjing Chen, Ilwoo Park, Gerd Melkus, Adam Elkhaled, John Kurhanewicz, Lisa Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, Rana Anjum, Andrew Bloecher, Myriam Chaumeil, James Rubenstein. Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):2840-2840.
    View on PubMed
  12. Khoan Vu, James Rubenstein, Gabriel N. Mannis, Jimmy Hwang, Huimin Geng. Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):4230-4230.
    View on PubMed
  13. Susan Wu, Steve Braunstein, James Rubenstein, Penny Sneed. RTHP-31. STEREOTACTIC RADIOSURGERY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi231-vi231.
    View on PubMed
  14. Rubenstein JL. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leuk Lymphoma. 2019 02; 60(2):281-283.
    View on PubMed
  15. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607.
    View on PubMed
  16. Damato BE, Bever GJ, Afshar AR, Rubenstein JL. Insights from a Case of Vitreoretinal Lymphoma. Ocul Oncol Pathol. 2019 Jan; 5(1):13-19.
    View on PubMed
  17. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):556-564.
    View on PubMed
  18. Brice Tiret, Adam Autry, Ilwoo Park, Ming Lu, Rana Anjum, Liza Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, James Rubenstein, Myriam M Chaumeil. EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Neuro-Oncology. 2017 Nov 6; 19(suppl_6):vi88-vi88.
    View on PubMed
  19. L. Nayak, F.M. Iwamoto, A.J. Ferreri, A. Santoro, S. Singer, C. Batlevi, T. Batchelor, J. Rubenstein, P. Johnston, R. Ramchandren, C. Soussain, J. Drappatz, K. Becker, M. Witzens-Harig, G. Illerhaus, A. Herrera, A. Masood, M. Shipp. CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. Hematological Oncology. 2017 Jun 1; 35(S2):420-421.
    View on PubMed
  20. J.L. Rubenstein, J. Hwang, G. Mannis. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Hematological Oncology. 2017 Jun 1; 35(S2):343-344.
    View on PubMed

Go to UCSF Profiles, powered by CTSI